bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings for bioMérieux S.A. (BIM.PA)
Earnings in 2023 (TTM): $456.19 M
According to bioMérieux S.A.'s latest financial reports the company's current earnings (TTM) are $456.19 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of bioMérieux S.A.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $456.19 M | $372.88 M |
| 2022 | $573.7 M | $471.73 M |
| 2021 | $780.27 M | $626.78 M |
| 2020 | $515.52 M | $421.68 M |
| 2019 | $332.21 M | $284.45 M |
| 2018 | $334.19 M | $267.56 M |
| 2017 | $304.47 M | $248.27 M |
| 2016 | $270.06 M | $186.75 M |
| 2015 | $183.73 M | $115.22 M |
| 2014 | $195.2 M | $140.66 M |
| 2013 | $253.49 M | $171.32 M |
| 2012 | $233.26 M | $140.14 M |
| 2011 | $247.96 M | $167.36 M |
| 2010 | $251.71 M | $166.84 M |
| 2009 | $211.25 M | $154.53 M |
| 2008 | $190.61 M | $135.55 M |
| 2007 | $161.2 M | $102.29 M |
| 2006 | $158.49 M | $109.8 M |
| 2005 | $144.42 M | $93.95 M |